Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York. more
Time Frame | INAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.38% | -2.06% | -0.55% |
1-Month Return | -19.03% | -1.92% | 2.72% |
3-Month Return | -18.64% | -10.4% | 7.66% |
6-Month Return | -73.15% | -4.6% | 10.15% |
1-Year Return | -80.11% | 4.06% | 27.53% |
3-Year Return | -95.41% | 1.94% | 32.31% |
5-Year Return | -97.32% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 96.00K | 96.00K | 251.00K | 1.10M | 2.50M | [{"date":"2019-12-31","value":3.84,"profit":true},{"date":"2020-12-31","value":3.84,"profit":true},{"date":"2021-12-31","value":10.04,"profit":true},{"date":"2022-12-31","value":44.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (96.00K) | (96.00K) | (251.00K) | (1.10M) | (2.50M) | [{"date":"2019-12-31","value":-9600000,"profit":false},{"date":"2020-12-31","value":-9600000,"profit":false},{"date":"2021-12-31","value":-25100000,"profit":false},{"date":"2022-12-31","value":-110300000,"profit":false},{"date":"2023-12-31","value":-250100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 5.07M | 8.56M | 14.65M | 28.52M | 30.34M | [{"date":"2019-12-31","value":16.7,"profit":true},{"date":"2020-12-31","value":28.21,"profit":true},{"date":"2021-12-31","value":48.3,"profit":true},{"date":"2022-12-31","value":94.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (5.13M) | (8.56M) | (14.65M) | (28.52M) | (30.34M) | [{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2852100000,"profit":false},{"date":"2023-12-31","value":-3033700000,"profit":false}] |
Total Non-Operating Income/Expense | (68.00K) | - | - | - | - | [{"date":"2019-12-31","value":-6800000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (5.13M) | (8.56M) | (14.65M) | (28.52M) | (30.01M) | [{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2852100000,"profit":false},{"date":"2023-12-31","value":-3000700000,"profit":false}] |
Income Taxes | (68.00K) | (118.30K) | 551.44K | (1.10M) | (32.84M) | [{"date":"2019-12-31","value":-12.33,"profit":false},{"date":"2020-12-31","value":-21.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-200.02,"profit":false},{"date":"2023-12-31","value":-5954.93,"profit":false}] |
Income After Taxes | (5.07M) | - | - | - | - | [{"date":"2019-12-31","value":-506600000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (5.13M) | (8.56M) | (14.65M) | (28.52M) | (30.01M) | [{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2852100000,"profit":false},{"date":"2023-12-31","value":-3000700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.13M) | (8.56M) | (14.65M) | (27.42M) | (30.01M) | [{"date":"2019-12-31","value":-513400000,"profit":false},{"date":"2020-12-31","value":-855700000,"profit":false},{"date":"2021-12-31","value":-1465300000,"profit":false},{"date":"2022-12-31","value":-2741800000,"profit":false},{"date":"2023-12-31","value":-3000700000,"profit":false}] |
EPS (Diluted) | (1.71) | (1.65) | (1.83) | (1.42) | (1.01) | [{"date":"2019-12-31","value":-170.99,"profit":false},{"date":"2020-12-31","value":-164.74,"profit":false},{"date":"2021-12-31","value":-183,"profit":false},{"date":"2022-12-31","value":-142,"profit":false},{"date":"2023-12-31","value":-101,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INAB | |
---|---|
Cash Ratio | 1.10 |
Current Ratio | 1.84 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INAB | |
---|---|
ROA (LTM) | -77.64% |
ROE (LTM) | -180.45% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.46 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.54 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INAB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.38 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
In8bio Inc (INAB) share price today is $0.2685
Yes, Indians can buy shares of In8bio Inc (INAB) on Vested. To buy In8bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of In8bio Inc (INAB) via the Vested app. You can start investing in In8bio Inc (INAB) with a minimum investment of $1.
You can invest in shares of In8bio Inc (INAB) via Vested in three simple steps:
The 52-week high price of In8bio Inc (INAB) is $1.93. The 52-week low price of In8bio Inc (INAB) is $0.22.
The price-to-earnings (P/E) ratio of In8bio Inc (INAB) is
The price-to-book (P/B) ratio of In8bio Inc (INAB) is 2.38
The dividend yield of In8bio Inc (INAB) is 0.00%
The market capitalization of In8bio Inc (INAB) is $20.41M
The stock symbol (or ticker) of In8bio Inc is INAB